neu's rationale for targeting tbi and retts

Not sure if anyone has seen this yet:

Treatment of Rett Syndrome With rhIGF-1

http://www.clinicaltrials.gov/ct2/show/study/NCT01253317?term=rett+syndrome+IGF-1&rank=1

On page 4 of the ten-year plan that I posted a few days ago (see here: http://www.1mind4research.org/sites/1mind4research.org/files/uploads/1m4R_Journal_LONG.pdf),
there's a fair bit of discussion about synaptic plasticity (which also is sometimes called neuronal plasticity).
Couldn't remember where i came across this term before, so looked over last years announcements and found it in the NEU AGM presentation posted last May on page 14 (see here: http://www.asx.com.au/asxpdf/20110531/pdf/41yyngmsjzf7fk.pdf), you'll see two graphs that summarize the effect of NNZ-2566 on neuronal plasticity in a mouse model of Rett Syndrome.

Continuing on in my research i also came across this from a group of researchers at MIT.

Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice

http://web.mit.edu/msur/www/publications/2009_TropeaGiacomettiWilsonetal.pdf

Interestingly, the above findings in the AGM announcement support similar findings reported by the researchers at MIT.

From what I understood, they found that (1-3) IGF-1 or glypromate, the parent molecule of NNZ-2566, had positive effects in the same mouse model, ie: impairment of synaptic plasticity also occurs following TBI and is thought to be associated with both cognitive impairment and susceptibility to seizures.

From this you can understand Neuren's rationale for targeting TBI and Rett Syndrome with the same drug.

What I've also come to understand is that many of the underlying pathologies are common across a surprisingly wide range of conditions. A good example is the role of neuroinflammation. That's why Neuren are targeting the inflammatory mechanism in both TBI and Rett Syndrome which, on the face of it, wouldn't seem to have much in common but, in fact, do. Further, many of the conditions overlap and frequently coexist ie: concussion and memory impairment, TBI and PTSD, TBI and depression, etc. If you look at the protocol for the ongoing NNZ-2566 trial, you'll see that Nueren included a wide range of endpoints that include mood, memory and cognitive function in addition to the more widely used functional outcome measures.

Isn't this exciting?

Good times ahead folks!